Kallen KJ - Search Results

1

Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection.

Petsch B, Schnee M, Vogel AB, Lange E, Hoffmann B, Voss D, Schlake T, Thess A, Kallen KJ, Stitz L, Kramps T. Petsch B, et al. Among authors: kallen kj. Nat Biotechnol. 2012 Dec;30(12):1210-6. doi: 10.1038/nbt.2436. Epub 2012 Nov 25. Nat Biotechnol. 2012. PMID: 23159882

2

Developing mRNA-vaccine technologies.

Schlake T, Thess A, Fotin-Mleczek M, Kallen KJ. Schlake T, et al. Among authors: kallen kj. RNA Biol. 2012 Nov;9(11):1319-30. doi: 10.4161/rna.22269. Epub 2012 Oct 12. RNA Biol. 2012. PMID: 23064118 Free PMC article. Review.

3

Highly potent mRNA based cancer vaccines represent an attractive platform for combination therapies supporting an improved therapeutic effect.

Fotin-Mleczek M, Zanzinger K, Heidenreich R, Lorenz C, Thess A, Duchardt KM, Kallen KJ. Fotin-Mleczek M, et al. Among authors: kallen kj. J Gene Med. 2012 Jun;14(6):428-39. doi: 10.1002/jgm.2605. J Gene Med. 2012. PMID: 22262664

4

A novel, disruptive vaccination technology: self-adjuvanted RNActive(®) vaccines.

Kallen KJ, Heidenreich R, Schnee M, Petsch B, Schlake T, Thess A, Baumhof P, Scheel B, Koch SD, Fotin-Mleczek M. Kallen KJ, et al. Hum Vaccin Immunother. 2013 Oct;9(10):2263-76. doi: 10.4161/hv.25181. Epub 2013 Jun 4. Hum Vaccin Immunother. 2013. PMID: 23921513 Free PMC article. Review.

5

A development that may evolve into a revolution in medicine: mRNA as the basis for novel, nucleotide-based vaccines and drugs.

Kallen KJ, Theß A. Kallen KJ, et al. Ther Adv Vaccines. 2014 Jan;2(1):10-31. doi: 10.1177/2051013613508729. Ther Adv Vaccines. 2014. PMID: 24757523 Free PMC article. Review.

6

A New RNA-Based Adjuvant Enhances Virus-Specific Vaccine Responses by Locally Triggering TLR- and RLH-Dependent Effects.

Ziegler A, Soldner C, Lienenklaus S, Spanier J, Trittel S, Riese P, Kramps T, Weiss S, Heidenreich R, Jasny E, Guzmán CA, Kallen KJ, Fotin-Mleczek M, Kalinke U. Ziegler A, et al. Among authors: kallen kj. J Immunol. 2017 Feb 15;198(4):1595-1605. doi: 10.4049/jimmunol.1601129. Epub 2017 Jan 11. J Immunol. 2017. PMID: 28077601

7

Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity.

Fotin-Mleczek M, Duchardt KM, Lorenz C, Pfeiffer R, Ojkić-Zrna S, Probst J, Kallen KJ. Fotin-Mleczek M, et al. Among authors: kallen kj. J Immunother. 2011 Jan;34(1):1-15. doi: 10.1097/CJI.0b013e3181f7dbe8. J Immunother. 2011. PMID: 21150709

8

The regulatory landscape for actively personalized cancer immunotherapies.

Britten CM, Singh-Jasuja H, Flamion B, Hoos A, Huber C, Kallen KJ, Khleif SN, Kreiter S, Nielsen M, Rammensee HG, Sahin U, Hinz T, Kalinke U. Britten CM, et al. Among authors: kallen kj. Nat Biotechnol. 2013 Oct;31(10):880-2. doi: 10.1038/nbt.2708. Nat Biotechnol. 2013. PMID: 24104749 No abstract available.

9

mRNA-based vaccines synergize with radiation therapy to eradicate established tumors.

Fotin-Mleczek M, Zanzinger K, Heidenreich R, Lorenz C, Kowalczyk A, Kallen KJ, Huber SM. Fotin-Mleczek M, et al. Among authors: kallen kj. Radiat Oncol. 2014 Aug 15;9:180. doi: 10.1186/1748-717X-9-180. Radiat Oncol. 2014. PMID: 25127546 Free PMC article.

10

A novel RNA-based adjuvant combines strong immunostimulatory capacities with a favorable safety profile.

Heidenreich R, Jasny E, Kowalczyk A, Lutz J, Probst J, Baumhof P, Scheel B, Voss S, Kallen KJ, Fotin-Mleczek M. Heidenreich R, et al. Among authors: kallen kj. Int J Cancer. 2015 Jul 15;137(2):372-84. doi: 10.1002/ijc.29402. Epub 2015 Jan 8. Int J Cancer. 2015. PMID: 25530186 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

55 results

Search Page